Evidence map›Paper›PMID 38611661›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Susceptibility-Weighted MRI for Predicting NF-2 Mutations and S100 Protein Expression in Meningiomas.

Sena Azamat, Buse Buz-Yalug, Sukru Samet Dindar, Kubra Yilmaz Tan, Alpay Ozcan, Ozge Can, Ayca Ersen Danyeli, M Necmettin Pamir, Alp Dincer, Koray Ozduman and 1 more

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Advancements in the application of MRI radiomics in meningioma.Radiation oncology (London, England) · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Sena AzamatInstitute of Biomedical Engineering, Bogazici University, Istanbul 34342, Turkey.
Buse Buz-YalugInstitute of Biomedical Engineering, Bogazici University, Istanbul 34342, Turkey.
Sukru Samet DindarElectrical and Electronics Engineering Department, Bogazici University, Istanbul 34342, Turkey.ORCID 0009-0009-4781-1728
Kubra Yilmaz TanDepartment of Medical Biotechnology, Acibadem University, Istanbul 34752, Turkey.
Alpay OzcanElectrical and Electronics Engineering Department, Bogazici University, Istanbul 34342, Turkey.
Ozge CanDepartment of Biomedical Engineering, Acibadem University, Istanbul 34752, Turkey.ORCID 0000-0002-2063-2502
Ayca Ersen DanyeliDepartment of Medical Pathology, Acibadem University, Istanbul 34752, Turkey.
M Necmettin PamirCenter for Neuroradiological Applications and Research, Acibadem University, Istanbul 34752, Turkey.
Alp DincerCenter for Neuroradiological Applications and Research, Acibadem University, Istanbul 34752, Turkey.
Koray OzdumanCenter for Neuroradiological Applications and Research, Acibadem University, Istanbul 34752, Turkey.
Esin Ozturk-IsikInstitute of Biomedical Engineering, Bogazici University, Istanbul 34342, Turkey.
Acıbadem University · TRBoğaziçi University · TRIstanbul Metropolitan Municipality · TR

Funding

Scientific and Technological Research Council of Turkey 119S520
6 · The paper itself

Abstract

S100 protein expression levels and neurofibromatosis type 2 (NF-2) mutations result in different disease courses in meningiomas. This study aimed to investigate non-invasive biomarkers of NF-2 copy number loss and S100 protein expression in meningiomas using morphological, radiomics, and deep learning-based features of susceptibility-weighted MRI (SWI). This retrospective study included 99 patients with S100 protein expression data and 92 patients with NF-2 copy number loss information. Preoperative cranial MRI was conducted using a 3T clinical MR scanner. Tumor volumes were segmented on fluid-attenuated inversion recovery (FLAIR) and subsequent registration of FLAIR to high-resolution SWI was performed. First-order textural features of SWI were extracted and assessed using Pyradiomics. Morphological features, including the tumor growth pattern, peritumoral edema, sinus invasion, hyperostosis, bone destruction, and intratumoral calcification, were semi-quantitatively assessed. Mann-Whitney U tests were utilized to assess the differences in the SWI features of meningiomas with and without S100 protein expression or NF-2 copy number loss. A logistic regression analysis was used to examine the relationship between these features and the respective subgroups. Additionally, a convolutional neural network (CNN) was used to extract hierarchical features of SWI, which were subsequently employed in a light gradient boosting machine classifier to predict the NF-2 copy number loss and S100 protein expression. NF-2 copy number loss was associated with a higher risk of developing high-grade tumors. Additionally, elevated signal intensity and a decrease in entropy within the tumoral region on SWI were observed in meningiomas with S100 protein expression. On the other hand, NF-2 copy number loss was associated with lower SWI signal intensity, a growth pattern described as "en plaque", and the presence of calcification within the tumor. The logistic regression model achieved an accuracy of 0.59 for predicting NF-2 copy number loss and an accuracy of 0.70 for identifying S100 protein expression. Deep learning features demonstrated a strong predictive capability for S100 protein expression (AUC = 0.85 ± 0.06) and had reasonable success in identifying NF-2 copy number loss (AUC = 0.74 ± 0.05). In conclusion, SWI showed promise in identifying NF-2 copy number loss and S100 protein expression by revealing neovascularization and microcalcification characteristics in meningiomas.

Indexed as

machine learningmeningiomaNF-2 mutationsS100 protein expressionsusceptibility-weighted MRI

Identifiers

PMID38611661
PMCPMC11012050
OpenAlexW4393356914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.